Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

GCA Therapeutics to Commercialize Achillion’s HBV Treatment in China

publication date: Feb 2, 2010
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Achillion Pharmaceuticals out-licensed the China rights for elvucitabine, to GCA Therapeutics, Ltd. (GCAT) of Jersey City, New Jersey. Elvucitabine is a nucleoside reverse transcriptase inhibitor (NRTI) for the treatment of both hepatitis B virus (HBV) and human immunodeficiency virus (HIV). GCAT has a China JV with Tianjing Institute of Pharmaceutical Research, which will be responsible for developing and commercializing the drug in China, Hong Kong and Taiwan. More details...

Stock Symbol: (NSDQ: ACHN)

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...